256 related articles for article (PubMed ID: 21327901)
1. [The role of tumour markers in diagnosis and management of testicular germ cell tumours].
Krege S; Albers P; Heidenreich A
Urologe A; 2011 Mar; 50(3):313-21. PubMed ID: 21327901
[TBL] [Abstract][Full Text] [Related]
2. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
3. Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment.
Dieckmann KP; Simonsen-Richter H; Kulejewski M; Anheuser P; Zecha H; Isbarn H; Pichlmeier U
Biomed Res Int; 2019; 2019():5030349. PubMed ID: 31275973
[TBL] [Abstract][Full Text] [Related]
4. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer.
Murez T; Fléchon A; Branger N; Savoie PH; Rocher L; Camparo P; Neuville P; Ferretti L; Van Hove A; Roupret M
Prog Urol; 2022 Nov; 32(15):1066-1101. PubMed ID: 36400478
[TBL] [Abstract][Full Text] [Related]
5. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
6. [CCAFU french national guidelines 2016-2018 on testicular germ cell tumors].
Durand X; Fléchon A; Murez T; Rocher L; Camparo P; Morel-Journel N; Savoie PH; Ferretti L; Sèbe P; Méjean A
Prog Urol; 2016 Nov; 27 Suppl 1():S147-S165. PubMed ID: 27846929
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic markers for germ cell neoplasms: from placental-like alkaline phosphatase to micro-RNAs.
Rajpert-De Meyts E; Nielsen JE; Skakkebaek NE; Almstrup K
Folia Histochem Cytobiol; 2015; 53(3):177-88. PubMed ID: 26306513
[TBL] [Abstract][Full Text] [Related]
8. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
[TBL] [Abstract][Full Text] [Related]
9. [Tumor markers in testicular cancer].
Mann K
Urologe A; 1990 Mar; 29(2):77-86. PubMed ID: 2158684
[TBL] [Abstract][Full Text] [Related]
10. [CCAFU Recommendations 2013: Testicular germ cell cancer].
Durand X; Rigaud J; Avancès C; Camparo P; Fléchon A; Murez T; Sèbe P; Culine S; Iborra F; Mottet N; Coloby P; Soulié M;
Prog Urol; 2013 Nov; 23 Suppl 2():S145-60. PubMed ID: 24485289
[TBL] [Abstract][Full Text] [Related]
11. The present and future of serum diagnostic tests for testicular germ cell tumours.
Murray MJ; Huddart RA; Coleman N
Nat Rev Urol; 2016 Dec; 13(12):715-725. PubMed ID: 27754472
[TBL] [Abstract][Full Text] [Related]
12. Serum tumour markers in germ cell tumours: From diagnosis to cure.
Pedrazzoli P; Rosti G; Soresini E; Ciani S; Secondino S
Crit Rev Oncol Hematol; 2021 Mar; 159():103224. PubMed ID: 33493632
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
14. [Clinical presentation of testicular germinal cancer].
Fernández Gómez JM; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; Escaf Barmadah S; García Rodríguez J; Pérez García FJ; Rodríguez Faba O; Jalón Monzón A
Arch Esp Urol; 2002 Oct; 55(8):915-22. PubMed ID: 12455282
[TBL] [Abstract][Full Text] [Related]
15. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.
von Eyben FE; Blaabjerg O; Madsen EL; Petersen PH; Smith-Sivertsen C; Gullberg B
Eur J Cancer; 1992; 28(2-3):410-5. PubMed ID: 1375486
[TBL] [Abstract][Full Text] [Related]
16. Serum markers in germ cell neoplasms.
Bartlett NL; Freiha FS; Torti FM
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1245-60. PubMed ID: 1723408
[TBL] [Abstract][Full Text] [Related]
17. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976-1980.
Nørgaard-Pedersen B; Schultz HP; Arends J; Brincker H; Krag Jacobsen G; Lindeløv B; Rørth M; Svennekjaer IL
Acta Radiol Oncol; 1984; 23(4):287-94. PubMed ID: 6208749
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor markers in the evaluation of male germ cell tumors.
Barlow LJ; Badalato GM; McKiernan JM
Nat Rev Urol; 2010 Nov; 7(11):610-7. PubMed ID: 21068762
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.
Gerl A; Clemm C; Lamerz R; Mann K; Wilmanns W
Eur J Cancer; 1993; 29A(7):961-5. PubMed ID: 7684597
[TBL] [Abstract][Full Text] [Related]
20. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?
Fosså SD; Qvist H; Stenwig AE; Lien HH; Ous S; Giercksky KE
J Clin Oncol; 1992 Apr; 10(4):569-73. PubMed ID: 1312586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
